Nitin Kapoor, chairman and general director of AstraZeneca Vietnam and Asia Area Frontier Markets and vice president of International Vaccines and Immune Therapies has won an award for Great Leadership from the British Chamber of Commerce (BritCham).
|Nitin Kapoor of AstraZeneca Vietnam receiving his award for Great Leadership |
Nitin Kapoor is a British business leader with nearly 30 years of extensive experience across the finance, healthcare, and pharmaceutical industries on several continents. He has led AstraZeneca’s ambitious strategy in Vietnam since 2018.
Under his steer, AstraZeneca Vietnam has become a market leader and a champion for public-private partnerships with the Vietnamese government and healthcare partners to reduce the burden of both infectious and non-communicable diseases (NCD) and promote sustainability. Kapoor has exemplified how visionary leadership can transform an organisation and make a meaningful impact on society.
Together with the award for Nitin Kapoor, AstraZeneca Vietnam has also received the Great Service to Health Award from BritCham in recognition of AstraZeneca Vietnam’s meaningful contribution to uplifting the local healthcare sector.
While its innovative medicines are improving the lives of nearly three million Vietnamese patients struggling with NCDs each year, the company’s COVID-19 vaccine, developed in partnership with the University of Oxford, was the first to be approved and used in Vietnam during the pandemic and has helped to protect millions of Vietnamese people.
|AstraZeneca Vietnam receiving the Great Service to Health Award |
In order to protect high-risk and immunocompromised individuals against COVID-19, the company is also delivering a long-acting antibody combination that has been available in Vietnam since March this year.
Kapoor said, “As a global biopharmaceutical company headquartered in the UK, AstraZeneca is honoured that our contributions to people and the society are recognised again by BritCham Vietnam. These awards are a great encouragement to us as we embark on a new journey of strategic, comprehensive partnership with Vietnam to bring quality healthcare and innovative medicines and vaccines to local communities. This recognition is for our leadership team, 500-plus employees in Vietnam, and many other global colleagues who remain as committed as ever to making health happen in Vietnam.”
AstraZeneca has run several impactful programmes in collaboration with the Ministry of Health and healthcare partners to promote disease awareness, prevention, and early detection.
Amongst them are the Healthy Lung Programme to improve the quality of outpatient management of asthma, COPD, and lung cancer, the Young Health Programme to prevent and reduce NCD risk behaviours amongst young people, and the CaReMe programme to transform the cardiovascular-renal-metabolic care ecosystem.
AstraZeneca is also cooperating with the World Economic Forum, the London School of Economics, and the Health Strategy and Policy Institute in the Partnership for Health System Sustainability and Resilience to recommend health policies that will help to holistically reinforce the Vietnamese health system and prepare for future risks.
These awards mark the latest acknowledgement of the company’s efforts in almost three decades of contribution to sustainable healthcare development in Vietnam. They add to the extensive list of recognitions that AstraZeneca has received in its long history with the nation.
In 2021, the company received BritCham’s Great Contribution to Healthcare and 25+ Years Milestone awards for its meaningful journey in the country.
The company also received the Minister of Health’s Certificate of Merit twice for excellent contributions to advancing cancer treatment (2019) and to the pandemic response (2020), amongst other industry awards.
AstraZeneca Vietnam's awards are part of the Great Awards programme organised by BritCham to honour British companies, organisations, and individuals with significant contributions to the UK-Vietnam relationship for over 30 years in sectors such as education, technology, banking, health, and science.